TY - JOUR
T1 - TDP-43 variants of frontotemporal lobar degeneration
AU - Bigio, Eileen H.
N1 - Funding Information:
Acknowledgments We would like to gratefully acknowledge the NU CNADC directed by Dr. M-Marcel Mesulam, the NU Lois Insolia ALS Center directed by Dr. Teepu Siddique, Manjari Mishra, and Katherine Gasho for histological and immunohistochemical expertise, the UT Southwestern ADC for the FTLD-TDP type 4 case, and, most importantly, the generous patients and families without whom these studies would not be possible. This study is supported in part by NIH grant AG13854
PY - 2011/11
Y1 - 2011/11
N2 - It has been only 5 years since the identification of TDP-43 as the major protein component of the ubiquitinated inclusions in FTLD-U. At that time, there were approximately a dozen papers about TDP-43; today, a "TDP-43" search reveals almost 600 papers. It is now clear that the majority of FTLD cases containing tau- and alpha-synuclein-negative, ubiquitin-positive inclusions (FTLD-U) are FTLD-TDP. The spectrum of TDP-43 proteinopathies includes FTLD-TDP with or without ALS, with or without mutations in GRN, VCP, or TARDBP, with or without chromosome 9p linkage, and sporadic and non-SOD1 familial ALS with or without FTLD-TDP. There are four sub-types of FTLD-TDP, and these correlate with specific clinical and genetic profiles. Sub-types are determined by the presence, predominance, and distribution of the various TDP-43 immunopositive insoluble aggregates-neuronal cytoplasmic inclusions, neuronal intranuclear inclusions, and dystrophic neurites. In this paper, FTLD-TDP pathologic sub-types will be described, and examples of each sub-type will be shown, and implications for future research will be discussed.
AB - It has been only 5 years since the identification of TDP-43 as the major protein component of the ubiquitinated inclusions in FTLD-U. At that time, there were approximately a dozen papers about TDP-43; today, a "TDP-43" search reveals almost 600 papers. It is now clear that the majority of FTLD cases containing tau- and alpha-synuclein-negative, ubiquitin-positive inclusions (FTLD-U) are FTLD-TDP. The spectrum of TDP-43 proteinopathies includes FTLD-TDP with or without ALS, with or without mutations in GRN, VCP, or TARDBP, with or without chromosome 9p linkage, and sporadic and non-SOD1 familial ALS with or without FTLD-TDP. There are four sub-types of FTLD-TDP, and these correlate with specific clinical and genetic profiles. Sub-types are determined by the presence, predominance, and distribution of the various TDP-43 immunopositive insoluble aggregates-neuronal cytoplasmic inclusions, neuronal intranuclear inclusions, and dystrophic neurites. In this paper, FTLD-TDP pathologic sub-types will be described, and examples of each sub-type will be shown, and implications for future research will be discussed.
KW - ALS
KW - Amyotrophic lateral sclerosis
KW - FTD
KW - FTLD-TDP
KW - FTLD-U
KW - Frontotemporal dementia
KW - GRN
KW - Progranulin
KW - TAR-DNA binding protein-43
KW - TARDBP, FTLD-U
KW - TDP-43
UR - http://www.scopus.com/inward/record.url?scp=80855143681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80855143681&partnerID=8YFLogxK
U2 - 10.1007/s12031-011-9545-z
DO - 10.1007/s12031-011-9545-z
M3 - Article
C2 - 21607722
AN - SCOPUS:80855143681
SN - 0895-8696
VL - 45
SP - 390
EP - 401
JO - Journal of Molecular Neuroscience
JF - Journal of Molecular Neuroscience
IS - 3
ER -